CEPI Advancing Vaccine Innovations and Speeding Up Vaccine Manufacturing

Advancing Vaccine Innovations for Future Epidemics and Pandemics 

CEPI is currently funding calls for Innovations to Prepare for Future Epidemics and Pandemics to support CEPI’s mission by advancing a broad range of vaccine innovations for pathogens with epidemic or pandemic potential, including novel pathogens capable of infecting and causing disease in humans (i.e., Disease X). 

Two focus areas are open for applications under this topic. Focus Area 1 will concentrate on advancing innovative rapid-response vaccine platforms that can transform the response to a future Disease X. Focus Area 2 will emphasise on developing new vaccine candidates against Lassa fever and Disease X exemplar viral families, including paramyxoviruses, arenaviruses, coronaviruses, phenuiviruses, hantaviruses and nairoviruses. 

Speeding Up Vaccine Manufacturing and Expanding Global Access  

CEPI’s new funding opportunity ‘Innovative analytical technologies to improve vaccine manufacturing speed and equitable access’, seeks to develop innovative analytical technologies for vaccines. The goal of this call is to reduce vaccine development, manufacturing and release times, and to lower costs, improve equitable deployment in low- to middle-income countries and enhance analytical insights for vaccines such as RNA, viral vectors or protein-based vaccines.